Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress

Climb Bio will present new clinical data on its budoprutug program at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden, from June 11-14, 2026. The presentation will include safety, B-cell depletion, and initial platelet data from the low dose cohort (250mg at 24 weeks) of the ongoing Phase 1b/2a trial in previously treated patients with primary immune thrombocytopenia (ITP). Budoprutug is a novel anti-CD19 monoclonal antibody with the potential to treat a broad range of B-cell mediated diseases, including pMN, ITP, and SLE.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.